Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biohaven Ltd. stock logo
BHVN
Biohaven
$14.44
-0.2%
$17.82
$13.87
$55.70
$1.48B0.951.28 million shs1.38 million shs
CorMedix Inc stock logo
CRMD
CorMedix
$16.56
+21.7%
$11.65
$3.61
$17.40
$923.09M1.621.26 million shs7.09 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$35.33
+2.0%
$33.64
$27.12
$60.90
$2.08B2.38970,671 shs925,745 shs
Vericel Corporation stock logo
VCEL
Vericel
$41.80
-0.5%
$41.46
$37.39
$63.00
$2.12B1.33411,151 shs360,901 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biohaven Ltd. stock logo
BHVN
Biohaven
0.00%-5.97%-7.43%-53.16%-56.78%
CorMedix Inc stock logo
CRMD
CorMedix
0.00%-6.52%+10.11%+26.37%+210.02%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%+3.34%+22.58%-22.92%-32.04%
Vericel Corporation stock logo
VCEL
Vericel
0.00%-1.52%+2.69%-12.35%-6.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biohaven Ltd. stock logo
BHVN
Biohaven
3.1634 of 5 stars
4.51.00.00.02.22.50.6
CorMedix Inc stock logo
CRMD
CorMedix
0.4631 of 5 stars
1.61.00.00.02.10.00.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.2245 of 5 stars
4.41.00.04.42.80.80.6
Vericel Corporation stock logo
VCEL
Vericel
2.312 of 5 stars
3.51.00.00.01.40.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biohaven Ltd. stock logo
BHVN
Biohaven
3.07
Buy$58.46305.00% Upside
CorMedix Inc stock logo
CRMD
CorMedix
3.17
Buy$15.83-4.39% Downside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4042.65% Upside
Vericel Corporation stock logo
VCEL
Vericel
3.00
Buy$61.1446.27% Upside

Current Analyst Ratings Breakdown

Latest CRMD, BHVN, VCEL, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
CorMedix Inc stock logo
CRMD
CorMedix
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
6/20/2025
CorMedix Inc stock logo
CRMD
CorMedix
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$13.00 ➝ $17.00
6/18/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$68.00 ➝ $55.00
6/16/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00
5/22/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
5/19/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.00
5/13/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.00
5/7/2025
CorMedix Inc stock logo
CRMD
CorMedix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $15.00
5/6/2025
CorMedix Inc stock logo
CRMD
CorMedix
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/A$4.19 per shareN/A
CorMedix Inc stock logo
CRMD
CorMedix
$43.47M25.84N/AN/A$1.40 per share11.83
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.76N/AN/A$8.07 per share4.38
Vericel Corporation stock logo
VCEL
Vericel
$237.22M8.87$0.31 per share134.47$5.92 per share7.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biohaven Ltd. stock logo
BHVN
Biohaven
-$846.42M-$9.36N/AN/AN/AN/A-257.07%-164.01%8/5/2025 (Estimated)
CorMedix Inc stock logo
CRMD
CorMedix
-$17.93M$0.2275.2817.62N/A20.81%22.57%17.02%8/13/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$10.36M$0.031,393.8095.00N/A1.25%1.09%0.73%7/30/2025 (Estimated)

Latest CRMD, BHVN, VCEL, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A
5/8/2025Q1 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million
5/6/2025Q1 2025
CorMedix Inc stock logo
CRMD
CorMedix
$0.25$0.30+$0.05$0.30$38.90 million$39.08 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
3/25/2025Q4 2024
CorMedix Inc stock logo
CRMD
CorMedix
$0.17$0.22+$0.05$0.22$27.46 million$30.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
CorMedix Inc stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biohaven Ltd. stock logo
BHVN
Biohaven
N/A
2.33
2.33
CorMedix Inc stock logo
CRMD
CorMedix
N/A
4.21
3.99
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.01
4.58

Institutional Ownership

CompanyInstitutional Ownership
Biohaven Ltd. stock logo
BHVN
Biohaven
88.78%
CorMedix Inc stock logo
CRMD
CorMedix
34.18%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
Biohaven Ltd. stock logo
BHVN
Biohaven
14.60%
CorMedix Inc stock logo
CRMD
CorMedix
5.30%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
Vericel Corporation stock logo
VCEL
Vericel
7.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
239102.11 million87.21 millionOptionable
CorMedix Inc stock logo
CRMD
CorMedix
3067.82 million64.23 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
30050.34 million46.72 millionOptionable

Recent News About These Companies

Vericel Corporation: Moving From Sell To Neutral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biohaven stock logo

Biohaven NYSE:BHVN

$14.44 -0.03 (-0.17%)
Closing price 03:59 PM Eastern
Extended Trading
$14.42 -0.02 (-0.10%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

CorMedix stock logo

CorMedix NASDAQ:CRMD

$16.56 +2.95 (+21.68%)
Closing price 04:00 PM Eastern
Extended Trading
$16.56 0.00 (-0.03%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$35.33 +0.69 (+1.99%)
Closing price 04:00 PM Eastern
Extended Trading
$35.97 +0.64 (+1.81%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Vericel stock logo

Vericel NASDAQ:VCEL

$41.80 -0.22 (-0.52%)
Closing price 04:00 PM Eastern
Extended Trading
$43.25 +1.45 (+3.47%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.